EFFECTOR THERAPEUTICS INC (EFTR) Stock Price, Forecast & Analysis
NASDAQ:EFTR • US28202V2079
EFTR Key Statistics, Chart & Performance
The current stock price of EFTR is 0.18 USD. In the past month the price decreased by -88.46%. In the past year, price decreased by -99.13%.
EFTR Technical Analysis
EFTR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EFTR. While EFTR seems to be doing ok healthwise, there are quite some concerns on its profitability.
EFTR Financial Highlights
Over the last trailing twelve months EFTR reported a non-GAAP Earnings per Share(EPS) of -13.08. The EPS decreased by -9.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -127.64% | ||
| ROE | -4187.55% | ||
| Debt/Equity | 0 |
EFTR Forecast & Estimates
8 analysts have analysed EFTR and the average price target is 11.22 USD. This implies a price increase of 6133.33% is expected in the next year compared to the current price of 0.18.
EFTR Ownership
EFTR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 402.079B | ||
| AMGN | AMGEN INC | 16.38 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 188.348B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 117.985B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 82.362B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 40.753B | ||
| INSM | INSMED INC | N/A | 31.174B | ||
| BIIB | BIOGEN INC | 12.92 | 28.692B | ||
| NTRA | NATERA INC | N/A | 28.683B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.502B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EFTR
Company Profile
eFFECTOR Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Solana Beach, California and currently employs 15 full-time employees. The company went IPO on 2021-01-08. eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The firm uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.
Company Info
EFFECTOR THERAPEUTICS INC
142 North Cedros Avenue, Suite B, Suite A
Solana Beach CALIFORNIA US
CEO: John M. Butler
Employees: 15
Phone: 18589258215
EFFECTOR THERAPEUTICS INC / EFTR FAQ
What does EFTR do?
eFFECTOR Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Solana Beach, California and currently employs 15 full-time employees. The company went IPO on 2021-01-08. eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The firm uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.
What is the stock price of EFFECTOR THERAPEUTICS INC today?
The current stock price of EFTR is 0.18 USD. The price decreased by -32.56% in the last trading session.
Does EFTR stock pay dividends?
EFTR does not pay a dividend.
What is the ChartMill rating of EFFECTOR THERAPEUTICS INC stock?
EFTR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does EFFECTOR THERAPEUTICS INC have?
EFFECTOR THERAPEUTICS INC (EFTR) currently has 15 employees.
Who owns EFFECTOR THERAPEUTICS INC?
You can find the ownership structure of EFFECTOR THERAPEUTICS INC (EFTR) on the Ownership tab.
What is the Short Interest ratio of EFFECTOR THERAPEUTICS INC (EFTR) stock?
The outstanding short interest for EFFECTOR THERAPEUTICS INC (EFTR) is 1.25% of its float.